Replies to post #4647 on BioCryst Pharmaceuticals,Inc. (BCRX)

[Femto99]

21%, not half. It is common for shorts to bet on the failure of a research stage biotech. However, with ORLADEYO $500m+ annual sales projection, we are instantly a commercial-stage pharmaceutical. I think the shorts are in bigger trouble than they were expecting.